"At Gibbs Cancer Center & Research Institute, we treat you like family. We provide you with the friendliness and warmth of a community hospital and the advanced level of care you’d expect from a large, academic medical center. Every patient’s case is reviewed by teams of healthcare professionals that specialize in each patient’s specific type of cancer – these meetings are called multidisciplinary conferences. With our commitment to bringing together multiple specialists to create the best treatment plan for you, and our strong clinical research program, we’re delivering the highest standard of patient-centered cancer care to the entire Upstate South Carolina region."

During the past decade, Gibbs Cancer Center-Pelham conducted 112 clinical trials. In the 10-year time frame, 112 clinical trials started and 51 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 40 clinical trials started and 44 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gibbs Cancer Center-Pelham" #1 sponsor was "National Cancer Institute (NCI)" with 63 trials, followed by "SWOG Cancer Research Network" with 26 trials sponsored, "Alliance for Clinical Trials in Oncology" with 17 trials sponsored, "NRG Oncology" with 13 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 13 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gibbs Cancer Center-Pelham" #1 collaborator was "National Cancer Institute (NCI)" with 87 trials as a collaborator, "NRG Oncology" with 25 trials as a collaborator, "Canadian Cancer Trials Group" with 8 trials as a collaborator, "AstraZeneca" with 2 trials as a collaborator and "Millennium Pharmaceuticals, Inc." with 2 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "Gibbs Cancer Center-Pelham" are "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Breast Cancer" (7 trials), "Invasive Breast Carcinoma" (7 trials) and "Recurrent Ovarian Carcinoma" (7 trials). Many other conditions were trialed in "Gibbs Cancer Center-Pelham" in a lesser frequency.

Most popular intervention types in "Gibbs Cancer Center-Pelham" are "Other" (106 trials), "Drug" (103 trials), "Biological" (52 trials), "Radiation" (41 trials) and "Procedure" (40 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (49 trials), "Laboratory Biomarker Analysis" (43 trials), "Questionnaire Administration" (35 trials), "Biospecimen Collection" (21 trials) and "Cisplatin" (19 trials). Other intervention names were less common.

The vast majority of trials in "Gibbs Cancer Center-Pelham" are 113 trials for "All" genders, 32 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are NaN active trials in "Gibbs Cancer Center-Pelham". undefined are not yet recruiting, 37 are recruiting, 78 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Gibbs Cancer Center-Pelham, 4 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Gibbs Cancer Center-Pelham, 2 "Phase 1" clinical trials were conducted, 60 "Phase 2" clinical trials and 90 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 10 trials that are defined as “Not Applicable".